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Background. There are challenges in the clinical diagnosis of drug-induced injury and in obtaining information on the reactivation
of human herpes viruses (HHV) during idiosyncratic adverse drug reactions. Objectives. (i) To develop a uniﬁed list of drugs
incriminated in drug-induced hepatotoxicity and severe cutaneous reactions, in which drug hypersensitivity leads to HHV-6
reactivation and further complication of therapy and recovery and (ii) to supplement the already available data on reporting
frequencies of liver- or skin-induced cases with knowledge of individual case reports, including HHV-6 reactivation and brieﬂy
introducing chromosomally integrated HHV-6. Data Sources and Extraction. Drugs identiﬁed as causes of (i) idiosyncratic
reactions, (ii) drug-induced hypersensitivity, drug-induced hepatotoxicity, acute liver failure, and Stevens-Johnson syndrome,
and (iii) human herpes virus reactivation in PubMed since 1997 have been collected and discussed. Results. Data presented in
this paper show that HHV-6 reactivation is associated with more severe organ involvement and a prolonged course of disease.
Conclusion. This analysis of HHV-6 reactivation associated with drug-induced severe cutaneous reactions and hepatotoxicity will
aid in causality assessment and clinical diagnosis of possible life-threatening events and will provide a basis for further patient
characterization and therapy.
1.Introduction
A hypersensitivity reaction (HSR) is a host-dependent
idiosyncratic adverse drug reaction (ADR) that cannot be
predicted by the dose, frequency, or length of the treatment.
Furthermore, animal models cannot predict an HSR. A
“true” HSR is deﬁned by the triad of fever, rash, and internal
organ involvement [1–6]. HSRs occur with an incidence of 1
in 1000 to 1 in 10000 drug exposures, with a mortality rate
approaching 10% [5–8]. Symptoms of HSR can range from
general manifestations, such as morbiliform rash, urticaria,
angioedema, fever, malaise, anaphylaxis, bronchospasm, and
erythema multiforme, to severe cutaneous adverse reactions
(SCAR) such as drug-induced hypersensitivity syndrome
(DIHS)/drug reaction with eosinophilia and systemic symp-
toms (DRESS), and Stevens-Johnson syndrome (SJS)/toxic
e p i d e r m a ln e c r o l y s i s( T E N )[ 2, 4–7, 9–11]. Cutaneous erup-
tions are reported in the vast majority of DIHS/DRESS
cases, often presenting as maculopapular rash or generalized
erythematous rash [7, 8]. The internal organ most often
aﬀected is the liver, with drug-induced liver injury (DILI)
presentingasanomaliesinliverfunctiontestsorthepresence
of hepatomegaly. Aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) were found to be increased
an average of 9-10-fold above the upper normal limits in
a literature review of 172 DRESS cases [7]. The presence
of serum bilirubin raised >3 times over the upper limit of
normal along with aminotransferase elevations is associated
with a more severe set of symptoms than isolated amino-
transferase abnormalities alone, an observation known as
Hy’s Law [12, 13]. Other internal organs, such as kidneys,
a r el e s so f t e na ﬀected [4, 7]. Hypereosinophilia is the2 International Journal of Hepatology
third most common symptom of DIHS/DRESS [7]. Skin
rash, liver involvement, high-grade fever, hypereosinophilia,
lymphadenopathy, and the increased presence of atypical
lymphocytes are symptoms associated with DIHS/DRESS
casesclassiﬁedas“probable/deﬁnite”basedontheRegiSCAR
scoring system [7].
Maculopapular rash, erythema multiforme, exfolia-
tive dermatitis, acute generalized exanthematous pustu-
lar dermatosis-like eruptions, and erythroderma are types
of cutaneous manifestations associated with DIHS, while
mucosal involvement is rare. On the other hand, skin and
mucosal involvement characterizes SJS/TEN [8]. A further
distinctionbetweenDIHS/DRESSandSJS/TENisthetimeto
onset of symptoms, which is often delayed (4-5 weeks) in the
former, while it occurs in the early stages of drug exposure
(approximately 3 weeks) in the latter [8].
Carbamazepine was the drug most often associated with
DRESS among 44 drugs linked to this reaction in 172 cases
reported over a period of 12 years [7]. Anticonvulsants such
as carbamazepine, phenytoin, phenobarbital, lamotrigine,
zonisamide, and sodium valproate are the class of drugs
most often related to DIHS/DRESS. Other pharmaceutical
agents, including allopurinol, nonsteroidal anti-inﬂammato-
ry drugs, chlormezanone, aminopenicillins, cephalosporins,
quinolones cycline antibiotics, and antiretrovirals, as well as
anti-infective sulfonamides, have also been implicated [6–
8, 11, 14–16].
SCAR development results in patient hospitalization,
and the culprit drug is interrupted on the ﬁrst day of
hospitalization. DILI is often diagnosed during the course
of the disease. Corticosteroids are the treatment most often
employed. The mean time to recovery was 6.4 weeks in 172
DRESS cases, while death was recorded in 9 (5.2%) patients.
Death was connected with a more severe course of reaction,
particularly observed in older patients, and often due to liver
failure [7].
While the precise mechanism of HSR is unknown,
various theories involve the interplay between metabolic and
immunologic factors [2, 4, 6], genetic predisposition, and,
more recently, infection with human herpes viruses (HHV),
particularly HHV-6 [8].
Drug metabolites bind to cellular macromolecules such
as proteins, creating covalent adducts that can serve as
antigenic stimuli for the immune system [4, 6]. Several
genetic factors are believed to predispose certain individuals
to this type of adverse reaction. The subset of the population
that is susceptible to HSRs carries defects in drug detoxifying
pathways (e.g., epoxide hydrolase), such that a greater
amount of a reactive drug metabolite is produced than
that which can be detoxiﬁed [2, 4, 6]. Additional genetic
predispositions that render certain individuals susceptible to
HSRs include human leukocyte antigen (HLA) alleles, which
are part of the major histocompatibility complex (discussed
by Neuman et al. [17]).
Reactivation of latent viral infections has been linked to
the development of more severe HSR symptoms, particularly
in the context of DIHS/DRESS. For example, HHV-6 reac-
tivation was associated with more severe organ involvement
andaprolongedcourseofdiseasein62of100DIHSpatients,
compared with the remaining 38 patients who did not
experience HHV-6 reactivation [18]. In the same study, all
ﬁvedeathsandtencasesofrenalfailurewereobservedamong
the62patientswithHHV-6DNAdetectedintheserum[18].
HHV-6 is a lymphotropic DNA virus belonging to the
Betaherpesviridae subfamily [19, 20]. Two genetic variants of
HHV-6 exist, HHV-6A and HHV-6B. While little is known
about HHV-6A, HHV-6B infection often occurs during the
ﬁrst 2 years of life and is associated with acute febrile illness
in young children and exanthem subitum in infants [19–
26]. HHV-6 infection can be accompanied by convulsions
and febrile status epilepticus. HHV-6 has been increasingly
recognized as a cause of hepatitis and liver failure, as well as
increased graft rejection and consequent decreased patient
survival [20–26]. The rate of infection approaches 100% in
individuals 2-3 years of age [21].
Following the initial infection, HHV-6B remains present
in a latent phase, and infection can be reactivated during
episodes of immunosuppression [20, 22, 24, 26]. Inherited
forms of both HHV-6A and HHV-6B have been shown
to integrate in chromosomes. This condition, known as
chromosomally integrated HHV-6 (CIHHV-6), occurs in
0.8% of control populations but is found in approximately
2% of patient populations in Europe, United States, and
the United Kingdom, with a lower rate in Japan. CIHHV-6
is characterized by the complete integration of the HHV-6
genome into the host germ line genome, such that CIHHV-
6D N Ai sf o u n di ne v e r yn u c l e a t e dc e l li nt h eb o d y[ 24, 27].
Persistentlyhighviralcopynumbersinwholebloodorserum
are observed in individuals with this condition [28, 29]. The
viral genome of CIHHV-6 is transmitted vertically in the
germline in a Mendelian manner [27]. Approximately 1% of
newbornsarediagnosedwithcongenitalHHV-6,allofwhich
areinfectedwithCIHHV-6,directlyorindirectly.Inasample
of 43 infants with congenital infection, the majority (86.0%)
were born with inherited CIHHV-6, while the remaining
(14.0%) were not born with CIHHV-6 but became infected
with HHV-6 transplacentally from their CIHHV-6-positive
mothers [30].
The cellular DNA damage machinery responds to virus
infection and the foreign genomes that accumulate in the
nuclei of infected cells. Many DNA viruses have been shown
to manipulate the cellular DNA damage response pathways
inordertocreateenvironmentsconducivetotheirownrepli-
cation. Some cellular factors are activated during infection
while others are inactivated [31].
Arbuckle et al. showed that HHV-6 DNA integrates
speciﬁcally and eﬃciently into the telomere sequences of
chromosomes. The integrated virus can be chemically acti-
vated with trichostatin A, a stimulatory compound known
to reactivate latent herpesviruses [32].
Active HHV-6 replication is determined by the presence
of HHV-6 DNA in serum, plasma, or cerebrospinal ﬂuid,
or by reverse-transcriptase polymerase chain reaction (RT-
PCR) in peripheral blood mononuclear cells (PBMC).
RT-PCR is the sole technique that allows active HHV-6
replication to be diﬀerentiated from inactive CIHHV-6 [33].
ItisimportantthatactiveHHV-6replicationisdiﬀerentiated
from CIHHV-6 [34].International Journal of Hepatology 3
Thepresentpaperreviewsrecentlypublishedcasereports
of SCAR (DIHS/DRESS and SJS/TEN) and DILI developed
secondary to drug exposure, with a particular focus on the
role of HHV-6 reactivation and CIHHV-6 presence in the
clinical outcome of the reaction. Our principal aim is to
addresstheroleofHHV-6reactivationinthecourseofHSRs,
particularly in DILI and DIHS/DRESS. In addition, we will
focus on the complex cellular responses triggered by HHV-6
reactivation.
2.MaterialsandMethods
Studies discussed in this paper were selected based on a
PubMed search of English language papers published in the
last 15 years (1997–2011) using keywords such as “HHV-
6 and hypersensitivity,” “HHV-6 and DIHS,” “HHV-6 and
DRESS,” “HHV-6 and SJS,” “HHV-6 and TEN,” “HHV-
6 reactivation and drug,” “HHV-6 and drug rash,” and
“chromosomally integrated HHV-6.” Case reports presented
deal largely with anticonvulsants and included HHV-6
reactivation. The selected case reports are part of a larger
database of HSR cases with HHV-6 reactivation. In addition,
our laboratory has studied HSRs and their mechanisms for
the last 25 years, and we discuss the cases based on our expe-
rience related to the laboratory and clinical manifestations.
3. Results
3.1. HSR and HHV-6 Reactivation. Following initial infec-
tion in early childhood, HHV-6 continues to exist in a latent
phase in the body. Consequently, HHV-6 DNA can be mea-
sured in diﬀerent body compartments in HHV-6-positive
individuals without activeinfection. Traceamounts of HHV-
6viralDNAwerealsodetectedbyreal-timequantitativePCR
in91(26.8%)of339pediatricpatientsdiagnosedandtreated
for acute lymphoblastic leukemia [34]. Low rates of HHV-6B
DNA were detected in whole blood (8.0%), PBMCs (16.5%),
and polymorphonuclear leukocytes (10.5%) belonging to
200 volunteers [54]. HHV-6A DNA was not observed in
this sample. The mean observed HHV-6B viral loads were
81copies/106 cells in whole blood, 62copies/106 cells in
PBMCs, and 34.5copies/106 cells in polymorphonuclear
leukocytes. Based on these ﬁndings, G´ eraudie et al. classify
healthy individuals as having HHV-6B viral loads below
100copies/106 cells [54]. HHV-6-DNA was positive in only
27 (39.1%) blood samples from 69 children undergoing
elective tonsillectomy for moderate tonsillar hyperplasia or
recurrent streptococcal infection without evidence of acute
HHV-6 infection, while evidence of HHV-6 DNA was found
in 100% of tonsil samples in the same population [55].
The common features of DIHS identiﬁed in a sample
of 7 patients were high fever (≥39◦C) in all patients, facial
edema in all patients, diﬀuse lymphadenopathy in 5 (71.4%)
patients, hypereosinophilia (>0.5 × 109/L) in 4 (57.1%)
patients, atypical circulating lymphocytes in 4 (57.1%)
patients, ALT elevated >3 times the reference level in 5
(71.4%)patients,andhypogammaglobulinemiain4(57.1%)
patients [14] .T h eo n s e to fD R E S St o o kp l a c ea f t e ram e a n
period of 25 days (5 days–6 weeks) of therapy with the
incriminated drug [14]. Similar ﬁndings are reported in
other cohorts of DIHS patients [15, 56].
Several studies suggest that HHV-6 reactivation can
only occur in susceptible individuals under conditions of
transient immunosuppression, such as those transiently
associated with the onset of DIHS [56, 57]. Lower serum
IgG levels were observed in 10 adult anticonvulsant-induced
HSR patients (mean 745mg/dL) compared to 15 controls
(P<0.001). Serum IgG levels continued to decrease for
several days after the drug was discontinued [57]. Similarly,
circulating levels of B cells were also decreased in DIHS
patients, compared to controls [15, 57]. In susceptible
individuals, continuous therapy with anticonvulsants, which
have been associated with DIHS, can lead to decreases
in B cells and subsequent hypogammaglobulinemia. Drug-
induced hypogammaglobulinemia could account for the
delay between DIHS onset and HHV-6 [57]. Moreover,
HHV-6 reactivation may occur at the same time, but it
cannot always be detected in blood, since it takes 2–4
weeks for antibodies to appear after infection or reactivation.
Because decreases in circulating IgG and B cell levels are
not observed with other hypersensitivity conditions such as
SJS/TEN, depressed levels of IgG and B cells can be used as
biomarkers for the onset of DIHS [57].
HHV-6 reactivation may be partially explained by the
immunosuppressive eﬀects of DIHS-related drugs. The mag-
nitude of inﬂammation is often proportional to the clinical
manifestations, while hypogammaglobulinemia and HHV-
6 reactivation worsen the clinical course of the disease [58].
Hypogammaglobulinemiaisthusanearlysymptomofsevere
DIHS.
A more detailed description of disease progression is
p r e s e n t e di nc a s er e p o r t s ,s o m eo fw h i c ha r es u m m a r i z e di n
Table 1 [35–52]. Fever was present in all patients described
in these reports. Edema, predominantly on the face, was
observed with a relatively high frequency [35, 37, 39–
44, 47–49, 52], as were lymphadenopathy [35, 36, 39, 41–
43, 45, 46, 49–51], hypereosinophilia [35–40, 42–52], and
atypical lymphocytes [35, 36, 38–40, 42, 44, 46, 47, 52].
Internal organ involvement manifested itself largely as liver
dysfunction, with elevated levels of liver enzymes [35–
46, 48–50, 52] and cholestatic hepatitis with hepatocellular
insuﬃciency [51]. Kidney failure was observed in a 75-
year-old lamotrigine patient [51]. Multiple organ failure
was observed in a couple of studies [47, 51], one of which
resulted in death [47]. Hypogammaglobulinemia, another
symptom of DIHS, was observed in a number of studies as
well [35, 38, 39, 45, 49].
The oﬀensive drug is immediately interrupted in DIHS
patients, and treatment with prednisolone is often used to
reverse the condition [15]. Symptoms begin to improve
gradually, but both fever and skin manifestations often
relapse approximately 2-3 weeks after the onset of DIHS.
There is a delay until antibodies to the virus are generated.
Therefore, there is a delay until the peak of the infection
is detected. Symptoms relapse coincides with detection of
HHV-6 reactivation, measured by circulating anti-HHV-6












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.International Journal of Hepatology 13
Anti-HHV-6 IgG levels are elevated after 3 weeks fol-
lowing the onset of the reaction (time of drug withdrawal),
but not after 2 weeks [58, 59]. Increases in HHV-6 DNA in
PBMCs were found to precede the increases in anti-HHV-6
IgG levels in anticonvulsant HSR patients and were absent
in controls [57]. The presence of HHV-6 DNA in PBMCs
was found to correlate with the magnitude of anti-HHV-6
antibody titers (P = 0.0002) [60]. Intermittent detection of
HHV-6 DNA in PBMCs was not indicative of illness, such
that HHV-6 DNA can be found in the PBMCs at low levels
in immunocompetent children, with and without symptoms
[60].
Signiﬁcantincreasesinanti-HHV-6IgGtiterswerenoted
in all 6 patients included in a study. HHV-6 infection was
conﬁrmed in all 6 patients by PCR in PBMCs. HHV-6
reactivation was observed between 17 and 27 days after the
onset of the reaction [56].
The presence of HHV-6 DNA in plasma or serum is
evidenceofactiveHHV-6infection.Inaddition,thepresence
of serum anti-HHV-6 IgM and increases in the levels of anti-
HHV-6 IgG levels are used to diﬀerentiate primary HHV-
6 infection (i.e., seroconversion) from HHV-6 reactivation.
Serum anti-HHV-6 IgG was detected in 7 DRESS patients
analyzed, with serum anti-HHV-6 IgM detected in only
4 (57.1%) patients. Seroconversion was diagnosed in 2
patients,inwhichserumanti-HHV-6IgMtiterswereinitially
undetectable and became detectable in subsequent serum
samples, coinciding with increases in anti-HHV-6 IgG titers
[14] .S e r o c o n v e r s i o ni sd e s c r i b e di nd e t a i li na5 6 - y e a r -
old male patient with aromatic anticonvulsant-induced HSR
[47].
Aside from the presentation of fever and cutaneous
symptoms, other features of HHV-6 reactivation can include
lymphadenopathy, hepatosplenomegaly, encephalitis caused
by the virus, and severe lymphocytopenia [56].
HHV-6 replication in hepatocytes led to severe hepatitis,
associated with elevated enzyme levels, in an 18-year-old
female [25]. Anti-HHV-6 antibody titers were elevated, as
were HHV-6 DNA levels [25]. Higher odds of detecting
HHV-6 DNA in PBMCs and liver biopsies were found in
cases of fulminant hepatic failure or acute decompensation
of chronic liver disease, compared to chronic liver disease
(P = 0.02), in a sample of 23 children (median age 24
months) with acute liver failure. Similarly, higher HHV-6
DNA levels were found in cases of fulminant hepatic failure
or acute decompensation of chronic liver disease, compared
to chronic liver disease cases (P = 0.0043). These ﬁndings
suggest that HHV-6 infection may cause liver failure in
children [20].
Tumor necrosis factor- (TNF) α and interleukin- (IL) 6
levels were initially elevated prior to HHV-6 reactivation in 4
(66.7%) of 7 patients in a study. Although initially high, IL-6
levels decreased just prior to HHV-6 reactivation. IL-6 levels
were once again elevated after HHV-6 infection in 5 (83.3%)
of 6 patients [56]. IL-6 and TNF-α are produced primarily
by monocytes and macrophages, the likely reservoir cells
of latent HHV-6. Yoshikawa et al. propose that HHV-
6 reactivation induces cytokine synthesis, which in turn
modulate clinical manifestations [56]. These cytokines likely
play an important role in viral reactivation, yet the low
number of patients analyzed in this study makes a deﬁnite
answer impossible [56]. Serum levels of IL-5, interferon
(IFN)-γ, and eosinophil cationic protein were increased on
day 29 and decreased on day 39 during an episode of
carbamazepine DIHS. IL-6 was also increased at this time
[58].
An interesting case of drug sensitization was observed
in a patient who developed symptoms of DIHS within a
few days of being exposed to the antibiotic cefaclor. This
patient was previously exposed to cefaclor during an episode
of carbamazepine-induced DIHS [58]. Slight increases in IL-
5, IL-6, IL-10, IFN-γ, and eosinophil cationic protein were
elevated in sera on day 6 of cefaclor DIHS [58]. A drug-
induced lymphocyte stimulation test using PBMCs showed
that the patient was sensitized to carbamazepine during the
ﬁrst episode, but not to cefaclor. Results of the test showed
sensitivitytocefaclorduringthesecondepisode[58].During
the ﬁrst episode, carbamazepine-induced HSR was diag-
nosed 17 days after the start of carbamazepine, consistent
with DIHS. Also, symptoms persisted after the drug was
interrupted,andthepatientrespondedtopulsedintravenous
(IV) methylprednisolone. In contrast, the patient developed
the symptoms much quicker during the second episode,
during which time the symptoms were milder and disap-
peared faster after interruption of cefaclor. The involvement
of HHV-6 during the ﬁrst episode was established with
anti-HHV-6 IgG titers and HHV-6 DNA. Absence of HHV-
6 reactivation could explain the milder symptoms during
the second episode [58]. The magnitude of inﬂammatory
cytokine increase was higher, and eosinophilia was more
pronounced during the more severe carbamazepine-induced
DIHS, prompting Aihara et al. to argue that HSR is mediated
by both elevated inﬂammatory cytokine levels and activated
eosinophils [58].
It is also possible that corticosteroids administered as
initial treatment for drug toxicity are involved in the
reactivation of HHV-6, Epstein-Barr virus (EBV), and
cytomegalovirus (CMV), which became active in the later
stage of the disease [15].
Anti-HHV-6 IgG titers were elevated in 7 DIHS patients
21–38 days after the onset of the reaction. Simultaneous
elevation in anti-HHV-7 IgG was observed in 6 patients.
An elevation in anti-CMV IgG was observed in all patients
35–54 days after the onset of the reaction. Only 2 patients
experienced an elevation in anti-EBV IgG, 37 and 48 days
after the onset of the reaction. Antibodies to herpes simplex
virus, varicella-zoster virus, human parvovirus B19, rubella,
and measles were not changed [15]. Viral DNA was detected
in whole blood in all patients for whom anti-viral IgG was
observed, and in serum for 6 of 7 HHV-6 patients, 5 of 6
HHV-7 patients, and all CMV and EBV patients. Rises in
CMV viral loads followed rises in HHV-6 viral loads by 10–
21 days [15]. Multiple viral reactivations in a single patient
are reported in another study as well [45].
HHV-6 and/or HHV-7 often reactivate ﬁrst, followed by
CMV and/or EBV [15]. There appears to be a correlation
betweenrelapseofsymptomsanddetectionofincreasedviral
loads for the virus that gets reactivated ﬁrst (i.e., HHV-6 or14 International Journal of Hepatology
HHV-7). Subsequent reactivation of CMV and EBV could be
asymptomatic [15]. Further immune system perturbations
broughtaboutbytheinitialHHVreactivationarebelievedto
be triggers for subsequent reactivation of other HHVs [15].
3.2. Chromosomally Integrated HHV-6. CIHHV-6 was de-
scribed and quantiﬁed in healthy blood donors and vari-
ous hospital populations (e.g., organ transplant recipients
and immunosuppressed patients) [28, 61–67]. The mean
viral loads in whole blood ranged from 106 copies/mL to
107 copies/mL [28, 62, 64].
Vertical transmission of inherited chromosomal inte-
g r a t i o ni sw e l ld o c u m e n t e d[ 61, 68]. In addition, there
are reports of CIHHV-6 acquisition through bone marrow
transplant, followed by the presence of HHV-6 in every cell
derived from hematopoietic stem cells [24, 69–71].
It is not known if CIHHV-6 can activate from its
integrated state in vivo,b u ts e v e r a ll i n e so fe v i d e n c es u g g e s t
that this is a signiﬁcant possibility. Integrated HHV-6 has
been shown to be activated in vitro [32] using histone
deacetylase inhibitors and other compounds known to
reactivate herpesviruses from latency [27]. As previously
discussed, transmission of CIHHV-6 from infected mothers
to their non-CIHHV-6 infants, via the placenta, is another
indicator that CIHHV-6 may be activated from its integrated
state in vivo [30]. Children suspected of encephalitis in the
United Kingdom had a four times greater rate of CIHHV-
6 than the general population [72], and liver transplant
patients with CIHHV-6 have higher rates of graft rejections
and opportunistic infections [62]. Marek’s Disease virus,
a herpesvirus associated with tumors in chickens, can
reactivate from its integrated state in vitro [27]. If speciﬁc
drugs can cause integrated virus to activate, then individuals
with CIHHV-6 may be at an increased risk for drug-induced
HSR.
Only a few cases of HSR in CIHHV-6 patients have
been reported. Watanabe et al. report the case of a 47-
year-old Japanese male with fever (38.8◦C) and generalized
erythematous rash 78 days after carbamazepine exposure
[73]. Mild hepatotoxicity (ALT 70IU/L, AST 73IU/L, γ-
glutamyl transpeptidase 129IU/L, and lactate dehydrogenase
686U/L)andhypogammaglobulinemia(IgG609mg/dL,IgA
34mg/dL and IgM 27mg/dL) were measured. An abdominal
skin biopsy revealed hydropic and vacuolar degeneration
of epidermal basal cells, lymphocytic inﬁltration in the
epidermis, and a dense upper dermal inﬁltrate consisting
mainly of mononuclear cells [73]. Anti-HHV-6 IgG titers
were increased 128-fold 6 weeks after the reaction onset,
while anti-HHV-6 IgM titers remained unchanged through-
out the course of the reaction, pointing towards HHV-6
reactivation. HHV-6 DNA was persistently high in serum
(>10000copies/mL) and whole blood. Fluorescent in situ
hybridization revealed CIHHV-6 on chromosome 1q44 [73].
HHV-6 DNA levels in primary infection and acute
reactivation are typically below 5.5 × 105 copies [27]. Of
interest, the only cases reported of viral loads above this
level (or in the same range as individuals with CIHHV-6)
appear to be those with graft-versus-host disease or DIHS,
two conditions that have very similar symptoms and courses
[18, 27, 74].
4. Discussion
In the present paper, we review cases of HSR associated
with HHV-6 reactivation. In the vast majority of patients,
HHV-6 infection occurs during infancy or early childhood
[60]. Following resolution of the primary infection, the virus
remains latent in salivary glands, PBMCs, and the central
nervous system. HHV-6 reactivates in immunosuppressed
individuals and is associated with fever, rash, encephalitis,
bone marrow suppression, and transplanted organ rejection.
PrimaryHHV-6infectioncanbeidentiﬁedbythepresenceof
HHV-6 DNA in the serum, plasma, or cerebrospinal ﬂuid, or
reversetranscriptionPCRintheabsenceofelevatedantibody
titers [60]. Reactivation is marked by detection of both viral
DNA and elevated anti-HHV-6 antibody titers [60]. As anti-
HHV-6 IgG levels increase during the course of the reaction,
anti-HHV-6 IgM levels remain constant around <1:20 in
patients with HHV-6 reactivation [42, 75].
HSRs seem to occur with almost a thousandfold higher
incidence in AIDS patients compared to immunocompetent
individuals exposed to the same medication, as there is a
much higher exposure to drugs in these patients, as well
as a much higher incidence of viral infections [76, 77].
Aside from a higher incidence of HSR, HIV positivity can
also lead to more severe symptoms, compared to HIV-
negative patients [77]. In addition, an in vitro study showed
increased DNA viral replication in PBMCs belonging to
DIHS patients that were depleted for natural killer cells
(NK)[78].Theseﬁndingspointtowardanextensiveimmune
barrier aimed against DIHS development, while immune
defects in components of these pathways can explain why
only a relatively small amount of the population exposed to
a drug will develop the reaction.
Interestingly, Kano et al. suggest that HHV-6 reactivation
is not a consequence, but rather a prerequisite for anti-
convulsant HSR [57]. The expansion of CD4+ T cells and
CD8+ T cells in response to HHV-6 reactivation seems to
be of extreme importance in the development of multiple
organ failure during the course of anticonvulsant HSR.
From their immunological ﬁndings, Kano et al. believe
that continuous anticonvulsant therapy leads to transient
immune dysfunction, marked by decreased IgG production
[57]. While T cells protect against reactivation of viruses
from a latent stage, antibodies prevent the dissemination
of reactivating lytic virus. Therefore, DIHS may occur
when transient drops in B cell counts and immunoglobulin
production allow HHV-6 to be reactivated from latency, in
conjunction with the presence of drug-speciﬁc T cells. The
likely explanation for the lag between start of anticonvulsant
therapy and onset of disease is that time is required for
immunoglobulin levels to drop below a certain threshold
[57].
An in vitro study using the human T cell line MT4 found
that therapeutic doses of both sodium valproate and carba-
mazepine led to enhanced HHV-6B replication in a dose-
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had no eﬀects on HHV-6B replication or cell proliferation
[79]. In vivo, there have been reports of phenytoin and
sulfonamide antibiotics leading to HHV-6 reactivation in
DIHS patients [42, 43, 47, 52].
As such, while widespread, HHV-6 infection is not
encountered in all DIHS cases. For example, HHV-6 DNA
was detected by PCR in blood or serum in a 25-year-old
female treated with phenobarbital, while it was absent in
a 21-year-old female treated with phenytoin [16]. Matsuda
et al. describe 2 cases of carbamazepine-induced DIHS in
which no viral reactivation was observed [53]. Symptoms,
including fever, skin eruptions, and liver involvement,
occurred between 22 days and 4 weeks after carbamazepine
initiation in the two patients, which is consistent with DIHS.
Furthermore, eosinophilia and a drop in white blood cell
count were observed in both patients [53].
HHV-6 reactivation typically occurs 2-3 weeks after the
development of rash in DIHS patients [8, 76]. Evidence of
this are elevated HHV-6 IgG titers and plasma HHV-6 DNA
[76]. HHV-6 reactivation is often accompanied by relapse
of fever and hepatitis [8]. A cascade of viral reactivation
can then be started, with HHV-6, EBV, and/or HHV-7 at
the top, followed, with some delay, by other herpes viruses,
particularly CMV. Reactivation of these viruses is followed
by development or exacerbation of clinical symptoms of
DIHS, including various organ failures [8, 76, 80]. Of par-
ticular interest is CMV reactivation, which can be followed
by transient fever, skin rash, myocarditis, pneumonia, or
gastrointestinal bleeding [8].
Clinical symptoms (fever, hepatitis, and/or skin rash)
correspond to the appearance of detectable HHV-6 DNA
levels. Fever and/or hepatitis are the most common clinical
features of HHV-6 reactivation in DIHS patients. Based
on these ﬁndings, HHV-6 reactivation leads to a more
severe course of disease in patients with DIHS [18]. HHV-
6 reactivation is associated with more severe organ involve-
ment and a prolonged course of the disease in patients
with drug rash and systemic symptoms, compared with
the remaining patients who did not experience HHV-6
reactivation [18]. Signiﬁcant detection of HHV-6 DNA
corresponds to the presence of anti-HHV-6 IgG titers, and
thereisapositivecorrelationbetweenHHV-6DNAdetection
and the development of fever and hepatitis [18].
While HHV-6 reactivation is a common feature of
DIHS/DRESS, HHV-6 DNA was not detected in 15 patients
with generalized morbilliform/maculopapular drug reac-
tions [81]. HHV-7, CMV, or EBV DNA was not detected in
any of the patients included in this study. In situ hybridiza-
tion revealed HHV-6 mRNA in a small subset of inﬁltrating
mononuclear cells around blood vessels and appendages in
DIHS patients only [81]. Similarly, only 1 (25.0%) of 4
SJS/TEN patients for whom data was available showed an
increase in anti-HHV-6 IgG titers from 1:10 to 1:1280
[52]. Aside from a lower likelihood of HHV-6 reactivation,
SJS/TEN is marked by a quicker onset of reaction than
DIHS/DRESS (2-3 weeks versus a mean 34 days) [52]. How-
ever,fever(>38.5◦C),leukocytosis,eosinophilia,andatypical
lymphocytosis were common features of both SJS/TEN
and DIHS/DRESS, whereas liver dysfunction was observed
predominantlyinSJS/TENpatientsandlymphnodeenlarge-
ment was observed predominantly in DIHS/DRESS patients.
Treatments for SJS/TEN included systemic corticosteroids in
7 (87.5%) patients and IV immunoglobulin in 1 (12.5%)
patient [52].
Furthermore, Teraki et al. warn that some of the clinical
features of anticonvulsant-induced SJS/TEN may diﬀer from
SJS/TEN induced by other drugs, such as a more delayed
onset of symptoms in the former category [52]. Additionally,
the rate of hepatic dysfunction and hematological anomalies
was also higher than that described with SJS/TEN induced
by other drugs [52]. HHV-6 reactivation and atypical lym-
phocytosis were observed in DIHS patients predominantly,
compared to SJS/TEN patients. The precise morphological
nature of the skin reaction is another criterion used to
diﬀerentiate DIHS from SJS/TEN. These ﬁndings should be
interpreted with care due to the low sample size [52].
Carbamazepine was associated with 12 (52.2%) of 23
anticonvulsant HSR cases reported in a cohort study. All
patients developed fever and pruritus. Maculopapular exan-
thematous eruptions were observed in 15 patients, erythro-
derma in 11 patients, exfoliative dermatitis in 3 patients,
bullous eruption in 1 patients, urticaria in 1 patient, and
purpura (vasculitis) in 2 patients [39]. There was no
relationship between thedrugusedand thelengthorseverity
of the reaction. In addition to the skin, 20 (87.0%) patients
had at least one other organ aﬀected by the reaction, while
8 (34.8%) patients had at least two other organs aﬀected
by the reaction. DILI was observed in 12 (52.2%) patients,
and kidney involvement was observed in 8 (34.8%) patients.
Other aﬀected organs include the spleen (splenomegaly),
the lung, the thyroid (hypothyroidism), the heart, and the
pancreas [39].
Drug-drug interactions are particularly problematic
when several pharmaceutical agents capable of inducting
HSR are administered simultaneously. For example, Conil-
leau et al. report the case of a child exposed intermittently to
two anticonvulsants prior to developing DIHS [48]. Despite
ethosuximide being interrupted prior to hospitalization and
sodium valproate being associated more often with DIHS,
it appears that the reaction was caused by the combination
of these two structurally unrelated anticovulsants, as a
patch test was positive for both ethosuximide and sodium
valproate [48]. In a separate case, an infant that was exposed
to carbamazepine, phenytoin, and phenobarbital presented
with initial HHV-6 infection. Despite the patient being
diagnosed with phenobarbital hypersensitivity [43], all three
of these aromatic antiepileptic drugs have the potential to
cause HSR [2]. Our group also describes patients susceptible
to multiple antiepileptics [17].
Minocycline-induced DIHS with EBV reactivation was
reported in a 24-year-old African American female. The
presenceofHHV-6wasnotassessedinthisstudy[82].HHV-
6reactivationwasobservedintwopatientswithsulfasalazine
severe hypersensitivity [83]. Sequential activation of HHV-
6, HHV-7, herpes simplex virus, and CMV was observed
in a 46-year-old male who developed DIHS after being
exposed to cyanamide, a drug used to control alcoholism
[84]. HHV-6 reactivation was observed in 2 elderly patients16 International Journal of Hepatology
with allopurinol DIHS [26, 79], and EBV reactivation was
observed in a 40-year-old black male with allopurinol
DIHS and pancreatitis [85]. The cause of the reaction was
unknown in an 18-year-old female with SJS/TEN exposed
to valacyclovir, promethazine, synthroid, belladonna, and
orthotricycline [26] .C a c o u be ta l .p r o v i d eac o m p r e h e n s i v e
list of 44 drugs associated with DIHS/DRESS [7].
In addition to anticonvulsants, patients can be exposed
to additional medication for the treatment of comorbid
diseases, opportunistic infections, or even for the manage-
ment of HSR symptoms (e.g., antibiotics or nonsteroidal
inﬂammatorydrugsadministeredforthetreatmentoffever).
Furthermore, epilepsy patients are often exposed to more
than one anticonvulsant, most of which are capable of
causing an HSR. While medication is interrupted at the
time of HSR diagnosis and the patient is encouraged to
avoid rechallenge with the drug that was deemed to have
initiated the reaction, it is still important that all medication
is considered and tested individually for its capacity to
initiate an HSR. Investigators seldom check to see if there is
an additive eﬀect between the incriminated anticonvulsant
and other medication, or if the anticonvulsant caused
the reaction on its own. Also, it is unlikely that HHV-6
reactivation is measured upon admission. As a result, it is
diﬃcult to establish whether the drug or the virus initiates
the reaction. Kano et al. argue that HHV-6 reactivation
creates an environment that favors DIHS development [57].
The same investigators report the case of a 46-year-old
woman who developed DIHS 4.5 months after initiating
therapy with zonisamide and corticosteroids [80]. Since the
reaction occurred well outside the time frame characteristic
of DIHS and since reactivation of herpes viruses was not
measured, it is possible that this phenomenon could have
created the conditions necessary for DIHS to occur in this
patient with long-term exposure to anticonvulsant therapy
[80].
The presence of proinﬂammatory cytokines during DILI
and SCAR is supported by ﬁndings that a signiﬁcantly
higher number of eosinophils was found both in the blood
and tissue of patients with a drug-induced maculopapular
exanthems, compared to control subjects with normal skin
and skin from patients with psoriasis [86]. Furthermore,
viral antigens can increase recruitment of eosinophils [87].
The presence of HLA-A∗3101 allele and homozygosity
for epoxide hydrolase 1 (EPHX1) single nucleotide poly-
morphism rs1051740 (T-C) in exon 3, associated with
modiﬁcations in epoxide hydrolase activity, were found in a
patient with anticonvulsant HSR, possibly triggered by HHV
reactivation, suggesting a genetic predisposition to HSR
upon HHV reactivation [41].
HHV-6 reactivation can be further observed in the
absence of an HSR and is primarily associated with hep-
atotoxicity. Phillips et al. were able to show with the help
of transmission electron microscopy that full and empty
virus capsids accumulate in the nucleus of hepatocytes, while
viral particles bud out into the nuclear envelope and the
cytoplasm [19]. Over the years, several drugs were used
to treat HHV reactivations per se,a sw e l la so p p o r t u n i s t i c
infections in HSR patients with HHV reactivation, including
idoxuridine [88], cytarabine [89], and vidarabine [90]. More
recently, ganciclovir was used in a patient with HHV-6 and
CMV reactivations [42]. Vancomycin was used to treat an
opportunistic infectionwithStaphylococcusaureusinaDIHS
patient with HHV-6 reactivation [44]. However, treatment
against HHV-6 reactivation is often withheld out of fear of
worsening the condition due to an increasing number of
drugs that the patient is exposed to [26].
Drug-induced adverse reactions represent a concern
for patients, clinicians, the pharmaceutical industry, and
health providers. Interestingly, very little mention of HHV-
6 reactivation is made in a comprehensive article discussing
DILI, including acute liver failure in major DILI registries
from Europe and the United States [91].
In conclusion, this paper provides a multifaceted assess-
ment of drugs implicated in HSR that have been reported to
induce HHV-6 reactivation. This information may facilitate
the possible link between the diagnosis of SCAR and DILI,
and HHV-6 reactivation.
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